Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03924323 · ClinicalTrials.gov registry record · Phase 4
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
A Phase 4 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 273
- Enrollment target
NCT03924323 is a Phase 4 study that has completed, run by AbbVie. The registered enrollment target is 273 participants.
The verdict
NCT03924323, a Phase 4 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in it called a placebo. The purpose of this research is to study the safety and effectiveness of escitalopram in minors with GAD.
Interventions
- OTHER Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2021-09-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03924323
The ClinicalTrials.gov registry entry for NCT03924323 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03924323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03924323 about?
NCT03924323 is a clinical study titled "A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder". This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in i...
What is the current status of trial NCT03924323?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 273 participants. The study started on 2019-05-30. Estimated completion is 2021-09-20.
What interventions are being tested in trial NCT03924323?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT03924323?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.